cd19 biotin Search Results


cd19 car detection  (Miltenyi Biotec)
96
Miltenyi Biotec cd19 car detection
Cd19 Car Detection, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd19 car detection/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
cd19 car detection - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
cd19 antibody (c19/366) [biotin]  (Bio-Techne corporation)
90
Bio-Techne corporation cd19 antibody (c19/366) [biotin]
Cd19 Antibody (C19/366) [Biotin], supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd19 antibody (c19/366) [biotin]/product/Bio-Techne corporation
Average 90 stars, based on 1 article reviews
cd19 antibody (c19/366) [biotin] - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd19 car biotin  (Miltenyi Biotec)
96
Miltenyi Biotec cd19 car biotin
(A) Schematic of sample analysis for <t>CD19-CAR</t> T cells at the pre-manufacturing and post-infusion time points. Created with BioRender. (B) Principal-component analysis (PCA) showing PC1 using genome-wide DNA methylation status for all available patient samples. n = 29 total patient samples. (C) Summary graph showing the number of differentially methylated regions (DMRs) longitudinally gained and lost across all patient samples relative to the associated GMP. n = 11 matched GMP and post-infusion patient samples. (D) Heatmap of the top methylated and demethylated CpG sites in all patient samples with longitudinal analysis among GMP, week 1, week 2, and week 3 time points. Clusters 1–8 are K-means clustering to identify groups of closely associated genes listed in . (E) Representative methylation and demethylation events at LEF1, PRF1, and TBET loci. Longitudinal samples are from a representative patient. Individual CpG sites are represented by vertical lines, with red indicating methylation and blue indicating lack of methylation. DMRs are represented by a green box, and enhancers are shown with a purple line. (F) Permutation test assessing enrichment of the DMRs conserved for all week 1–3 samples at enhancer sites defined by FANTOM . n = 12 post-infusion patient samples. (G) Transcription factor consensus sequence analysis of both the loss of methylation and gain of methylation DMRs conserved for all CD8 + CD19-CAR T cell post-infusion samples. n = 12 post-infusion patient samples.
Cd19 Car Biotin, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd19 car biotin/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
cd19 car biotin - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
biotinylated cd19 antibody  (Miltenyi Biotec)
95
Miltenyi Biotec biotinylated cd19 antibody
(A) Schematic of sample analysis for <t>CD19-CAR</t> T cells at the pre-manufacturing and post-infusion time points. Created with BioRender. (B) Principal-component analysis (PCA) showing PC1 using genome-wide DNA methylation status for all available patient samples. n = 29 total patient samples. (C) Summary graph showing the number of differentially methylated regions (DMRs) longitudinally gained and lost across all patient samples relative to the associated GMP. n = 11 matched GMP and post-infusion patient samples. (D) Heatmap of the top methylated and demethylated CpG sites in all patient samples with longitudinal analysis among GMP, week 1, week 2, and week 3 time points. Clusters 1–8 are K-means clustering to identify groups of closely associated genes listed in . (E) Representative methylation and demethylation events at LEF1, PRF1, and TBET loci. Longitudinal samples are from a representative patient. Individual CpG sites are represented by vertical lines, with red indicating methylation and blue indicating lack of methylation. DMRs are represented by a green box, and enhancers are shown with a purple line. (F) Permutation test assessing enrichment of the DMRs conserved for all week 1–3 samples at enhancer sites defined by FANTOM . n = 12 post-infusion patient samples. (G) Transcription factor consensus sequence analysis of both the loss of methylation and gain of methylation DMRs conserved for all CD8 + CD19-CAR T cell post-infusion samples. n = 12 post-infusion patient samples.
Biotinylated Cd19 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated cd19 antibody/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
biotinylated cd19 antibody - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
anti cd19  (Miltenyi Biotec)
95
Miltenyi Biotec anti cd19
(A) Schematic of sample analysis for <t>CD19-CAR</t> T cells at the pre-manufacturing and post-infusion time points. Created with BioRender. (B) Principal-component analysis (PCA) showing PC1 using genome-wide DNA methylation status for all available patient samples. n = 29 total patient samples. (C) Summary graph showing the number of differentially methylated regions (DMRs) longitudinally gained and lost across all patient samples relative to the associated GMP. n = 11 matched GMP and post-infusion patient samples. (D) Heatmap of the top methylated and demethylated CpG sites in all patient samples with longitudinal analysis among GMP, week 1, week 2, and week 3 time points. Clusters 1–8 are K-means clustering to identify groups of closely associated genes listed in . (E) Representative methylation and demethylation events at LEF1, PRF1, and TBET loci. Longitudinal samples are from a representative patient. Individual CpG sites are represented by vertical lines, with red indicating methylation and blue indicating lack of methylation. DMRs are represented by a green box, and enhancers are shown with a purple line. (F) Permutation test assessing enrichment of the DMRs conserved for all week 1–3 samples at enhancer sites defined by FANTOM . n = 12 post-infusion patient samples. (G) Transcription factor consensus sequence analysis of both the loss of methylation and gain of methylation DMRs conserved for all CD8 + CD19-CAR T cell post-infusion samples. n = 12 post-infusion patient samples.
Anti Cd19, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd19/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
anti cd19 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
biotin anti cd19  (Cytek Biosciences)
93
Cytek Biosciences biotin anti cd19
(A) Schematic of sample analysis for <t>CD19-CAR</t> T cells at the pre-manufacturing and post-infusion time points. Created with BioRender. (B) Principal-component analysis (PCA) showing PC1 using genome-wide DNA methylation status for all available patient samples. n = 29 total patient samples. (C) Summary graph showing the number of differentially methylated regions (DMRs) longitudinally gained and lost across all patient samples relative to the associated GMP. n = 11 matched GMP and post-infusion patient samples. (D) Heatmap of the top methylated and demethylated CpG sites in all patient samples with longitudinal analysis among GMP, week 1, week 2, and week 3 time points. Clusters 1–8 are K-means clustering to identify groups of closely associated genes listed in . (E) Representative methylation and demethylation events at LEF1, PRF1, and TBET loci. Longitudinal samples are from a representative patient. Individual CpG sites are represented by vertical lines, with red indicating methylation and blue indicating lack of methylation. DMRs are represented by a green box, and enhancers are shown with a purple line. (F) Permutation test assessing enrichment of the DMRs conserved for all week 1–3 samples at enhancer sites defined by FANTOM . n = 12 post-infusion patient samples. (G) Transcription factor consensus sequence analysis of both the loss of methylation and gain of methylation DMRs conserved for all CD8 + CD19-CAR T cell post-infusion samples. n = 12 post-infusion patient samples.
Biotin Anti Cd19, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotin anti cd19/product/Cytek Biosciences
Average 93 stars, based on 1 article reviews
biotin anti cd19 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
anti idiotype cd19 car fmc63  (Miltenyi Biotec)
93
Miltenyi Biotec anti idiotype cd19 car fmc63
(A) Schematic of sample analysis for <t>CD19-CAR</t> T cells at the pre-manufacturing and post-infusion time points. Created with BioRender. (B) Principal-component analysis (PCA) showing PC1 using genome-wide DNA methylation status for all available patient samples. n = 29 total patient samples. (C) Summary graph showing the number of differentially methylated regions (DMRs) longitudinally gained and lost across all patient samples relative to the associated GMP. n = 11 matched GMP and post-infusion patient samples. (D) Heatmap of the top methylated and demethylated CpG sites in all patient samples with longitudinal analysis among GMP, week 1, week 2, and week 3 time points. Clusters 1–8 are K-means clustering to identify groups of closely associated genes listed in . (E) Representative methylation and demethylation events at LEF1, PRF1, and TBET loci. Longitudinal samples are from a representative patient. Individual CpG sites are represented by vertical lines, with red indicating methylation and blue indicating lack of methylation. DMRs are represented by a green box, and enhancers are shown with a purple line. (F) Permutation test assessing enrichment of the DMRs conserved for all week 1–3 samples at enhancer sites defined by FANTOM . n = 12 post-infusion patient samples. (G) Transcription factor consensus sequence analysis of both the loss of methylation and gain of methylation DMRs conserved for all CD8 + CD19-CAR T cell post-infusion samples. n = 12 post-infusion patient samples.
Anti Idiotype Cd19 Car Fmc63, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti idiotype cd19 car fmc63/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
anti idiotype cd19 car fmc63 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
biotin anti cd19 miltenyi  (Miltenyi Biotec)
94
Miltenyi Biotec biotin anti cd19 miltenyi
(A) Schematic of sample analysis for <t>CD19-CAR</t> T cells at the pre-manufacturing and post-infusion time points. Created with BioRender. (B) Principal-component analysis (PCA) showing PC1 using genome-wide DNA methylation status for all available patient samples. n = 29 total patient samples. (C) Summary graph showing the number of differentially methylated regions (DMRs) longitudinally gained and lost across all patient samples relative to the associated GMP. n = 11 matched GMP and post-infusion patient samples. (D) Heatmap of the top methylated and demethylated CpG sites in all patient samples with longitudinal analysis among GMP, week 1, week 2, and week 3 time points. Clusters 1–8 are K-means clustering to identify groups of closely associated genes listed in . (E) Representative methylation and demethylation events at LEF1, PRF1, and TBET loci. Longitudinal samples are from a representative patient. Individual CpG sites are represented by vertical lines, with red indicating methylation and blue indicating lack of methylation. DMRs are represented by a green box, and enhancers are shown with a purple line. (F) Permutation test assessing enrichment of the DMRs conserved for all week 1–3 samples at enhancer sites defined by FANTOM . n = 12 post-infusion patient samples. (G) Transcription factor consensus sequence analysis of both the loss of methylation and gain of methylation DMRs conserved for all CD8 + CD19-CAR T cell post-infusion samples. n = 12 post-infusion patient samples.
Biotin Anti Cd19 Miltenyi, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotin anti cd19 miltenyi/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
biotin anti cd19 miltenyi - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
cd19 biotin antibody  (Enzo Biochem)
90
Enzo Biochem cd19 biotin antibody
(A) Schematic of sample analysis for <t>CD19-CAR</t> T cells at the pre-manufacturing and post-infusion time points. Created with BioRender. (B) Principal-component analysis (PCA) showing PC1 using genome-wide DNA methylation status for all available patient samples. n = 29 total patient samples. (C) Summary graph showing the number of differentially methylated regions (DMRs) longitudinally gained and lost across all patient samples relative to the associated GMP. n = 11 matched GMP and post-infusion patient samples. (D) Heatmap of the top methylated and demethylated CpG sites in all patient samples with longitudinal analysis among GMP, week 1, week 2, and week 3 time points. Clusters 1–8 are K-means clustering to identify groups of closely associated genes listed in . (E) Representative methylation and demethylation events at LEF1, PRF1, and TBET loci. Longitudinal samples are from a representative patient. Individual CpG sites are represented by vertical lines, with red indicating methylation and blue indicating lack of methylation. DMRs are represented by a green box, and enhancers are shown with a purple line. (F) Permutation test assessing enrichment of the DMRs conserved for all week 1–3 samples at enhancer sites defined by FANTOM . n = 12 post-infusion patient samples. (G) Transcription factor consensus sequence analysis of both the loss of methylation and gain of methylation DMRs conserved for all CD8 + CD19-CAR T cell post-infusion samples. n = 12 post-infusion patient samples.
Cd19 Biotin Antibody, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd19 biotin antibody/product/Enzo Biochem
Average 90 stars, based on 1 article reviews
cd19 biotin antibody - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


(A) Schematic of sample analysis for CD19-CAR T cells at the pre-manufacturing and post-infusion time points. Created with BioRender. (B) Principal-component analysis (PCA) showing PC1 using genome-wide DNA methylation status for all available patient samples. n = 29 total patient samples. (C) Summary graph showing the number of differentially methylated regions (DMRs) longitudinally gained and lost across all patient samples relative to the associated GMP. n = 11 matched GMP and post-infusion patient samples. (D) Heatmap of the top methylated and demethylated CpG sites in all patient samples with longitudinal analysis among GMP, week 1, week 2, and week 3 time points. Clusters 1–8 are K-means clustering to identify groups of closely associated genes listed in . (E) Representative methylation and demethylation events at LEF1, PRF1, and TBET loci. Longitudinal samples are from a representative patient. Individual CpG sites are represented by vertical lines, with red indicating methylation and blue indicating lack of methylation. DMRs are represented by a green box, and enhancers are shown with a purple line. (F) Permutation test assessing enrichment of the DMRs conserved for all week 1–3 samples at enhancer sites defined by FANTOM . n = 12 post-infusion patient samples. (G) Transcription factor consensus sequence analysis of both the loss of methylation and gain of methylation DMRs conserved for all CD8 + CD19-CAR T cell post-infusion samples. n = 12 post-infusion patient samples.

Journal: Cell reports

Article Title: CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia

doi: 10.1016/j.celrep.2021.110079

Figure Lengend Snippet: (A) Schematic of sample analysis for CD19-CAR T cells at the pre-manufacturing and post-infusion time points. Created with BioRender. (B) Principal-component analysis (PCA) showing PC1 using genome-wide DNA methylation status for all available patient samples. n = 29 total patient samples. (C) Summary graph showing the number of differentially methylated regions (DMRs) longitudinally gained and lost across all patient samples relative to the associated GMP. n = 11 matched GMP and post-infusion patient samples. (D) Heatmap of the top methylated and demethylated CpG sites in all patient samples with longitudinal analysis among GMP, week 1, week 2, and week 3 time points. Clusters 1–8 are K-means clustering to identify groups of closely associated genes listed in . (E) Representative methylation and demethylation events at LEF1, PRF1, and TBET loci. Longitudinal samples are from a representative patient. Individual CpG sites are represented by vertical lines, with red indicating methylation and blue indicating lack of methylation. DMRs are represented by a green box, and enhancers are shown with a purple line. (F) Permutation test assessing enrichment of the DMRs conserved for all week 1–3 samples at enhancer sites defined by FANTOM . n = 12 post-infusion patient samples. (G) Transcription factor consensus sequence analysis of both the loss of methylation and gain of methylation DMRs conserved for all CD8 + CD19-CAR T cell post-infusion samples. n = 12 post-infusion patient samples.

Article Snippet: Human CD8 + CD19-CAR T cells were stained with the following antibodies: CD45 - FITC (BD Bioscience, Cat# 555482, Clone: HI30) CD19 CAR - Biotin (Miltenyi, Cat# 130-115-965) Anti-biotin - PE (Miltenyi, Cat# 130-111-068, Clone: REA746) CD3 - APC (TONBO Bioscience, Cat# 20-0038-1500, Clone: UCHTI) CD14 – APC Cy7 (BD Bioscience, Cat# 333945, Clone: MφP9) CD16 – APC Cy7 (BD Bioscience, Cat# 563919, Clone: 3G8) CD8 – BV510 (BD Bioscience, Cat# 563919, Clone: SK1) CD4- BV786 (Biolegend, Cat# 317442, Clone OKT4)

Techniques: Genome Wide, DNA Methylation Assay, Methylation, Sequencing

(A) GO for the conserved post-infusion DMRs derived for all week 1–3 CD8 + CD19-CAR T cells. n = 12 post-infusion patient samples. (B) PCA of healthy donor naive (n = 4), stem-memory (Tscm, n = 3), central-memory (Tcm, n = 3), effector-memory (Tem, n = 3), and n = 13 CD8 + CD19-CAR T cells isolated longitudinally from patients post-infusion.

Journal: Cell reports

Article Title: CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia

doi: 10.1016/j.celrep.2021.110079

Figure Lengend Snippet: (A) GO for the conserved post-infusion DMRs derived for all week 1–3 CD8 + CD19-CAR T cells. n = 12 post-infusion patient samples. (B) PCA of healthy donor naive (n = 4), stem-memory (Tscm, n = 3), central-memory (Tcm, n = 3), effector-memory (Tem, n = 3), and n = 13 CD8 + CD19-CAR T cells isolated longitudinally from patients post-infusion.

Article Snippet: Human CD8 + CD19-CAR T cells were stained with the following antibodies: CD45 - FITC (BD Bioscience, Cat# 555482, Clone: HI30) CD19 CAR - Biotin (Miltenyi, Cat# 130-115-965) Anti-biotin - PE (Miltenyi, Cat# 130-111-068, Clone: REA746) CD3 - APC (TONBO Bioscience, Cat# 20-0038-1500, Clone: UCHTI) CD14 – APC Cy7 (BD Bioscience, Cat# 333945, Clone: MφP9) CD16 – APC Cy7 (BD Bioscience, Cat# 563919, Clone: 3G8) CD8 – BV510 (BD Bioscience, Cat# 563919, Clone: SK1) CD4- BV786 (Biolegend, Cat# 317442, Clone OKT4)

Techniques: Derivative Assay, Isolation

(A) Cross-sectional analysis of methylation-based multipotency index (MPI) measurement for CD8 + CD19-CAR T cells. n = 13 patient samples. (B) Longitudinal analysis of MPI measurement for CD8 + CD19-CAR T cells. n = 19 patient samples. (C) Linear regression of GMP MPI versus week 1 post-infusion CD8 + CD19-CAR T cell quantity (ug DNA on a log scale) determined from peripheral blood. n = 12 patient samples.

Journal: Cell reports

Article Title: CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia

doi: 10.1016/j.celrep.2021.110079

Figure Lengend Snippet: (A) Cross-sectional analysis of methylation-based multipotency index (MPI) measurement for CD8 + CD19-CAR T cells. n = 13 patient samples. (B) Longitudinal analysis of MPI measurement for CD8 + CD19-CAR T cells. n = 19 patient samples. (C) Linear regression of GMP MPI versus week 1 post-infusion CD8 + CD19-CAR T cell quantity (ug DNA on a log scale) determined from peripheral blood. n = 12 patient samples.

Article Snippet: Human CD8 + CD19-CAR T cells were stained with the following antibodies: CD45 - FITC (BD Bioscience, Cat# 555482, Clone: HI30) CD19 CAR - Biotin (Miltenyi, Cat# 130-115-965) Anti-biotin - PE (Miltenyi, Cat# 130-111-068, Clone: REA746) CD3 - APC (TONBO Bioscience, Cat# 20-0038-1500, Clone: UCHTI) CD14 – APC Cy7 (BD Bioscience, Cat# 333945, Clone: MφP9) CD16 – APC Cy7 (BD Bioscience, Cat# 563919, Clone: 3G8) CD8 – BV510 (BD Bioscience, Cat# 563919, Clone: SK1) CD4- BV786 (Biolegend, Cat# 317442, Clone OKT4)

Techniques: Methylation

(A) PCA using DNA methylation profiles of naive (n = 2), progenitor-exhausted (n = 2), and fully exhausted HIV tetramer+ (n = 4) CD8 + T cells for comparison with the GMP (n = 13) and weeks 1 (n = 4), 2 (n = 5), and 3 (n = 3) CD8 + CD19-CAR T cell profiles. (B) Summary pie charts for methylation status of DMRs residing within transitory-exhaustion-associated genes. (C) UMAP analysis of single-cell RNA sequencing data from an independent dataset obtained from CD19-CAR T cell infusion product and post-infusion early (1–2 weeks), late (~1 month), and very late (~80–100 days) time points. The left panel shows the distribution of cells based on the time point, and the smaller right panels show the expression of CX3CR1, BATF, LEF1, and TOX among the cells.

Journal: Cell reports

Article Title: CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia

doi: 10.1016/j.celrep.2021.110079

Figure Lengend Snippet: (A) PCA using DNA methylation profiles of naive (n = 2), progenitor-exhausted (n = 2), and fully exhausted HIV tetramer+ (n = 4) CD8 + T cells for comparison with the GMP (n = 13) and weeks 1 (n = 4), 2 (n = 5), and 3 (n = 3) CD8 + CD19-CAR T cell profiles. (B) Summary pie charts for methylation status of DMRs residing within transitory-exhaustion-associated genes. (C) UMAP analysis of single-cell RNA sequencing data from an independent dataset obtained from CD19-CAR T cell infusion product and post-infusion early (1–2 weeks), late (~1 month), and very late (~80–100 days) time points. The left panel shows the distribution of cells based on the time point, and the smaller right panels show the expression of CX3CR1, BATF, LEF1, and TOX among the cells.

Article Snippet: Human CD8 + CD19-CAR T cells were stained with the following antibodies: CD45 - FITC (BD Bioscience, Cat# 555482, Clone: HI30) CD19 CAR - Biotin (Miltenyi, Cat# 130-115-965) Anti-biotin - PE (Miltenyi, Cat# 130-111-068, Clone: REA746) CD3 - APC (TONBO Bioscience, Cat# 20-0038-1500, Clone: UCHTI) CD14 – APC Cy7 (BD Bioscience, Cat# 333945, Clone: MφP9) CD16 – APC Cy7 (BD Bioscience, Cat# 563919, Clone: 3G8) CD8 – BV510 (BD Bioscience, Cat# 563919, Clone: SK1) CD4- BV786 (Biolegend, Cat# 317442, Clone OKT4)

Techniques: DNA Methylation Assay, Comparison, Methylation, RNA Sequencing, Expressing

(A) Schematic depiction of a CD19-CAR T cell quantity relative to antigen-positive cells during a primary and secondary immune response. (B) Top panel: longitudinal graph of CD19-CAR T cell quantity and antigen-positive B cells from representative patient 5. Bottom panel: summary graph of CD19-CAR T cell expansion during a primary response to antigen (initial infusion) versus during endogenous CD19+ B cell recovery. n = 5 patient samples. (C) Patients #4 and #6 CAR T cell vector copy is calculated at the given time points relative to the overall quantity of DNA from the PBMCs. DNA methylation profiles at LEF1, CX3CR1, BATF, PDCD1, TIGIT, and TOX loci from patient 6 GMP and week 2 CD8 + CD19-CAR T cells as well as a Tpex sample are shown. Individual CpG sites are represented by vertical lines, with red indicating methylation and blue indicating a lack of methylation. DMRs are represented by a green box, and enhancers are shown with a purple line.

Journal: Cell reports

Article Title: CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia

doi: 10.1016/j.celrep.2021.110079

Figure Lengend Snippet: (A) Schematic depiction of a CD19-CAR T cell quantity relative to antigen-positive cells during a primary and secondary immune response. (B) Top panel: longitudinal graph of CD19-CAR T cell quantity and antigen-positive B cells from representative patient 5. Bottom panel: summary graph of CD19-CAR T cell expansion during a primary response to antigen (initial infusion) versus during endogenous CD19+ B cell recovery. n = 5 patient samples. (C) Patients #4 and #6 CAR T cell vector copy is calculated at the given time points relative to the overall quantity of DNA from the PBMCs. DNA methylation profiles at LEF1, CX3CR1, BATF, PDCD1, TIGIT, and TOX loci from patient 6 GMP and week 2 CD8 + CD19-CAR T cells as well as a Tpex sample are shown. Individual CpG sites are represented by vertical lines, with red indicating methylation and blue indicating a lack of methylation. DMRs are represented by a green box, and enhancers are shown with a purple line.

Article Snippet: Human CD8 + CD19-CAR T cells were stained with the following antibodies: CD45 - FITC (BD Bioscience, Cat# 555482, Clone: HI30) CD19 CAR - Biotin (Miltenyi, Cat# 130-115-965) Anti-biotin - PE (Miltenyi, Cat# 130-111-068, Clone: REA746) CD3 - APC (TONBO Bioscience, Cat# 20-0038-1500, Clone: UCHTI) CD14 – APC Cy7 (BD Bioscience, Cat# 333945, Clone: MφP9) CD16 – APC Cy7 (BD Bioscience, Cat# 563919, Clone: 3G8) CD8 – BV510 (BD Bioscience, Cat# 563919, Clone: SK1) CD4- BV786 (Biolegend, Cat# 317442, Clone OKT4)

Techniques: Cell Recovery, Plasmid Preparation, DNA Methylation Assay, Methylation

KEY RESOURCES TABLE

Journal: Cell reports

Article Title: CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia

doi: 10.1016/j.celrep.2021.110079

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Human CD8 + CD19-CAR T cells were stained with the following antibodies: CD45 - FITC (BD Bioscience, Cat# 555482, Clone: HI30) CD19 CAR - Biotin (Miltenyi, Cat# 130-115-965) Anti-biotin - PE (Miltenyi, Cat# 130-111-068, Clone: REA746) CD3 - APC (TONBO Bioscience, Cat# 20-0038-1500, Clone: UCHTI) CD14 – APC Cy7 (BD Bioscience, Cat# 333945, Clone: MφP9) CD16 – APC Cy7 (BD Bioscience, Cat# 563919, Clone: 3G8) CD8 – BV510 (BD Bioscience, Cat# 563919, Clone: SK1) CD4- BV786 (Biolegend, Cat# 317442, Clone OKT4)

Techniques: Recombinant, DNA Methylation Assay, Methylation, Software, Methylation Sequencing, Flow Cytometry